Abstract
Context:
Circulating tumor DNA (ctDNA) is a promising biomarker in cancer.
Materials and methods:
We generated xenograft models of cancer and detected ctDNA in plasma by qRCR targeting human AluJ sequences.
Results:
Our assay reached single cell sensitivity in vitro and a correlation between ctDNA amount and tumor size was observed in vivo. Treatment with a mitogen activated protein kinase kinase (MEK)-inhibitor (BAY 869766) reduced ctDNA levels. Using this assay, we also confirmed that high levels of cell-free DNA are found in cancer patients compared to healthy individuals.
Discussion and conclusion:
We show that ctDNA may be useful biomarker for monitoring tumor growth and treatment response.
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Biomarkers, Tumor / blood*
-
Breast Neoplasms / blood*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / pathology
-
Case-Control Studies
-
Cell Line, Tumor
-
Colorectal Neoplasms / blood*
-
Colorectal Neoplasms / drug therapy
-
Colorectal Neoplasms / pathology
-
DNA / blood*
-
Diphenylamine / administration & dosage
-
Diphenylamine / analogs & derivatives
-
Female
-
Humans
-
Kinetics
-
Male
-
Mice
-
Mice, Nude
-
Real-Time Polymerase Chain Reaction / standards
-
Reference Standards
-
Sulfonamides / administration & dosage
-
Tumor Burden
-
Xenograft Model Antitumor Assays / methods*
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
-
Sulfonamides
-
DNA
-
Diphenylamine